ASCO 2024 preview – jury still out on AbbVie's cancer push
SEZ6 looks promising but early, while questions remain around toxicity with AbbVie's cMet ADCs.
Agenus tries again with the FDA
A July meeting with the FDA could determine whether Agenus’s bot-bal combo has a shot at a 2024 filing.
Erasca doubles down on RAS
The young company’s eighth licensing deal brings in two RAS-targeting projects from Joyo.
EHA 2024 preview – Novartis doubles up
The conference’s abstract drop features ASC4First in its plenary session.
ESMO Breast Cancer 2024 – Olema digs deep to declare victory
Plenty of questions remain about the latest palazestrant data drop as investors hope for a Novartis buyout.
